(HealthDay)—Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared
Continue reading »Home »
mypharmacynews.com
Home »
(HealthDay)—Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared
Continue reading »